NL-OMON41936
Completed
Not Applicable
A Phase I study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of HTX-011-19 (a long acting formulation of 5% bupivacaine and 0.15% meloxicam) and HTX-011-49 (a long acting formulation of 2.5% bupivacaine and 0.075% meloxicam) after subcutaneous administration in healthy subjects. - HTX C2014-02
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- post-operative pain
- Sponsor
- Heron Therapeutics, Inc.
- Enrollment
- 46
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subject has signed the informed consent form prior to study participation.
- •2\. Subject is a healthy male or female volunteer between 18 and 55 years old (extremes inclusive).
- •3\. Subject has a body weight between 55 kg and 100 kg and a BMI between 18 and 30 kg/m2 (extremes inclusive).
- •4\. Subject can stay in study center for 6 days and return to study center for 2 consecutive days thereafter, and again on Day 12 (± 2 days).
- •5\. Subject has the ability to lie in a semi\-recumbent position for at least 1\.5 hours.
- •6\. Subject is appropriate for the study in the judgment of the investigator, based on physical examination, laboratory tests, and subject\*s interview.
- •7\. Subject has a skin\-type I or II (Fitzpatrick).
- •8\. Subject is willing to use adequate contraception from the time of dosing until 90 days after the follow\-up visit. o For male subjects: subjects with female partner of childbearing potential must agree to use a highly effective form of birth control, which entails the use of oral, injected or implanted hormonal methods of contraception or intra\-uterine device/system by the female partner, in combination with a barrier method (e.g. condom, diaphragm, cervical cap with spermicide) during the study and for 90 days after discontinuation of treatment. Furthermore male subjects must agree not to donate sperm during participation in the trial and for 90 days after discontinuation of treatment; For female subjects: confirmed post\-menopausal women, or female subjects agreeing to use a highly effective form of birth control, which entails the use of oral, injected or implanted hormonal methods of contraception or intra\-uterine device/system in combination with a barrier method (e.g. condom, diaphragm, cervical cap with spermicide) during the study and for 90 days after discontinuation of treatment
Exclusion Criteria
- •1\. Subject has a medical history of allergies including hypersensitivity against drug or clinically significant allergies, incl. asthma, urticaria, or allergic\-type reactions after taking aspirin or other NSAIDs.
- •2\. Subject has clinically significant abnormalities of hepatic, renal, respiratory system, endocrine system, nervous system, immune system, hematologic, psychiatric, cardiovascular system, cancer or has a history of cancer.
- •3\. Subject has an abnormal laboratory result judged by the investigator as being clinically significant.
- •4\. Subject has a positive urinary drug screen (incl. amphetamine, barbiturates, benzodiazepines, cocaine, marijuana, methadone, methamphetamine, morphine, phencyclidine, and tricyclic antidepressants).
- •5\. Subject has a positive test for HIV antibody, HBsAg, or HCV antibody.
- •6\. Subject has a QTc (Bazet) prolongation greater than or equal to 450 ms, or has significant electrocardiogram (ECG) abnormalities.
- •7\. Subject is a heavy smoker (\> 10 cigarettes or equivalents per day).
- •8\. Subject is unwilling or unable to refrain from smoking while in the clinical research unit.
- •9\. Subject has tattoos on the skin areas to be treated.
- •10\. Subject has a history of hypersensitivity reactions for any IMP constituent including bupivacaine and other amide\-type local anesthetics, and meloxicam.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A Phase 1 study to assess the safety, tolerability, and immunogenicity of VN-0200 after intramuscular injection in Japanese healthy adults and elderly subjectsPrevention of respiratory syncytial virusJPRN-jRCT2031210069Inoguchi Akihiro48
Completed
Phase 1
Safety and pharmacokinetics study in healthy Japanese volunteersJPRN-jRCT2051210087Owada Yasuko48
Recruiting
Phase 1
Phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in men with biochemical recurrence of prostate cancerbiochemical recurrence after curativelyintended therapy for localized PCDRKS00031816niversitätsklinikum Tübingen38
Active, not recruiting
Not Applicable
Clinical trial to assess the safety, tolerability, pharmacokinetics and anti-tumor activity of HM95573 in solid tumorNeoplasmsKCT0001539Hanmi Pharm72
Completed
Phase 1
Inhalation of Leukotriene B4 (LTB4) in patients suffering from BronchiectasisACTRN12614001199606TB4 Sweden AB30